PTC Therapeutics Inc (PTCT)
40.86
+0.46
(+1.15%)
USD |
NASDAQ |
Nov 05, 16:00
40.86
0.00 (0.00%)
After-Hours: 20:00
PTC Therapeutics Research and Development Expense (Annual): 666.56M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 666.56M |
| December 31, 2022 | 651.50M |
| December 31, 2021 | 540.68M |
| December 31, 2020 | 477.64M |
| December 31, 2019 | 257.45M |
| December 31, 2018 | 171.98M |
| December 31, 2017 | 117.46M |
| Date | Value |
|---|---|
| December 31, 2016 | 117.63M |
| December 31, 2015 | 121.82M |
| December 31, 2014 | 79.84M |
| December 31, 2013 | 54.88M |
| December 31, 2012 | 46.14M |
| December 31, 2011 | 58.68M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
257.45M
Minimum
2019
666.56M
Maximum
2023
518.77M
Average
540.68M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Pfizer Inc | 10.68B |
| Vertex Pharmaceuticals Inc | 3.163B |
| BridgeBio Pharma Inc | 455.71M |
| Cassava Sciences Inc | 89.42M |
| Crinetics Pharmaceuticals Inc | 168.53M |